Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 234-243

  Seely, Kathryn A ^a   Lapoint, Jeff ^b   Moran, Jeffery H ^a,c   Fattore, Liana ^d  

^a ARKANSAS DEPARTMENT OF HEALTH   (United States)

^b NEW YORK CITY POISON CONTROL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CNR National Research Council of Italy   (Italy)

Author keywords

'Legal highs'; Intoxication; K2; Marijuana alternative; Spice; Synthetic cannabinoid

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3 [2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL]CYCLOHEXANOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AM 2201; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABIS; CYCLOHEXYLPHENOL; DESIGNER DRUG; DEXANABINOL; DRONABINOL; JWH 073; JWH 122; JWH 200; JWH 205; JWH 210; SPICE DRUG; UNCLASSIFIED DRUG;

BRAIN ATROPHY; CHEMICAL COMPOSITION; DRUG ABUSE; DRUG DETERMINATION; DRUG MARKETING; HUMAN; INTOXICATION; LAW; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PSYCHOSIS; REVIEW; TANDEM MASS SPECTROMETRY;

ANIMALS; CANNABINOIDS; DESIGNER DRUGS; DRUG AND NARCOTIC CONTROL; DRUG USERS; HUMANS; INDOLES; NAPHTHALENES;

EID: 84866989897     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.017     Document Type: Review

References (125)

1. Akirav I. The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci 2011, 5:34-39.
2. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
3. American Association of Poison Control Centre (AAPCC) Fake marijuana spurs more than 4,500 calls to US Poison Centers Available at, (accessed May 13, 2011). http://www.aapcc.org/dnn/Portals/0/prrel/updatedk2-may112011.pdf.
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
5. Ashton C.H., Moore P.B. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011, 124:250-261.
6. Atwood B.K., Huffman J., Straiker A., Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharmacol 2010, 160:133-140.
7. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009, 2009(44):832-837.
8. Balster R.L., Prescott W.R. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 1992, 16:55-62.
9. Barrett R.L., Wiley J.L., Balster R.L., Martin B.R. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology 1995, 118:419-424.
10. Brents L.K., Reichard E.E., Zimmerman S.M., Moran J.H., Fantegrossi W.E., Prather P.L. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011, 6:e21917.
11. Brents L.K., Gallus-Zawada A., Radominska-Pandya A., Vasiljevik T., Prisinzano T.E., Fantegrossi W.E., et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 2012, 83:952-961.
12. Brown K. New Zealand bans synthetic cannabinoids. BMJ 2011, 343:d5395. 2011 Aug 23. 10.1136/bmj.d5395.
13. Bryner, J., 2010. Fake weed, real drug: K2 causing hallucinations in teens. Live Science. March 3, 2010. (accessed Mar 16, 2010). http://www.livescience.com/health/fake-marijuana-k2-hallucinations-100303.html.
14. Carroll F.I., Lewin A.H., Mascarella S.W., Seltzman H.H., Reddy P.A. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 2012, 1248:18-38.
15. Castellanos D., Singh S., Thornton G., Avila M., Moreno A. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011, 49:347-349.
16. Chang C.E., Ai R., Gutierrez M., Marsella M.J. Homology modelling of cannabinoid receptors: discovery of cannabinoid analogues for therapeutic use. Methods Mol Biol 2012, 819:595-613.
17. Chimalakonda K.C., Bratton S.M., Le V.H., Yiew K.H., Dineva A., Moran C.L., et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 2011, 39:1967-1976.
18. Chimalakonda K.C., Moran C.L., Kennedy P.D., Endres G.W., Uzieblo A., Dobrowolski P.J., et al. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem 2011, 83:6381-6388.
19. Coulter C., Garnier M., Moore C. Synthetic cannabinoids in oral fluid. J Anal Toxicol 2011, 35:424-430.
20. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992, 35:124-135.
21. Desroches J., Beaulieu P. Opioids and cannabinoids interactions: involvement in pain management. Curr Drug Targets 2010, 11:462-473.
22. Di Marzo V., Petrocellis L.D. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006, 57:553-574.
23. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:377-391.
24. Dresen S., Ferreirós N., Pütz M., Westphal F., Zimmermann R., Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010, 45:1095-1232.
25. Dresen S., Kneisel S., Weinmann W., Zimmermann R., Auwärter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 2011, 46:163-171.
26. Drug Enforcement Administration (DEA) Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I. Fed Regist 2011, 76(40). Available at: http://www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr0301.htm (accessed August 8, 2011).
27. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009, 259:413-431.
28. Eissenstat M.A., Bell M.R., D'Ambra T.E., Alexander E.J., Daum S.J., Ackerman J.H., et al. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 1995, 38:3094-3105.
29. ElSohly M.A., Gul W., Elsohly K.M., Murphy T.P., Madgula V.L., Khan S.I. Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 2011, 35:487-495.
30. Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 2012, 209:357-381.
31. European Monitoring Centre for Drugs, Drug Addiction (EMCDDA) Understanding the 'Spice' phenomenon 2009, EMCDDA, Lisbon, Available at: http://www.emcdda.europa.eu/html.cfm/index90917EN.html (accessed April 23, 2011).
32. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH018 may precipitate psychosis in vulnerable individuals. Addiction 2010, 105:1859-1860.
33. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011, 117:152-157.
34. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011, 5:60-66.
35. Fernández-Ruiz J., Romero J., Velasco G., Tolón R.M., Ramos J.A., Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci 2007, 28:39-45.
36. Ferraro L., Tomasini M.C., Cassano T., Bebe B.W., Siniscalchi A., O'Connor W.T., et al. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J Neurosci Res 2001, 66:298-302.
37. Ferraro L., Tomasini M.C., Gessa G.L., Bebe B.W., Tanganelli S., Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 2001, 11:728-733.
38. Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs. Arch Pharmacol 2010, 381:563-572.
39. Fišar Z. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry 2012, 2011 Dec 30, [Epub ahead of print].
40. Forrester M.B., Kleinschmidt K., Schwarz E., Young A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 2011, 30:351-358.
41. Gerra G., Zaimovic A., Gerra M.L., Ciccocioppo R., Cippitelli A., Serpelloni G., et al. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov 2010, 5:46-52.
42. Ghosh S., Preet A., Groopman J.E., Ganju R.K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 2006, 43:2169-2179.
43. 9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther 2012, 340:37-45.
44. Gottardo R., Chiarini A., Dal Prà I., Seri C., Rimondo C., Serpelloni G., et al. Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J Mass Spectrom 2012, 47:141-146.
45. Griffiths P., Sedefov R., Gallegos A., Lopez D. How globalization and market innovation challenge how we think and respond to drug use: 'Spice' a case study. Addiction 2010, 105:951-953.
46. Grigoryev A., Melnik A., Savchuk S., Simonov A., Rozhanets V. Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:2519-2526.
47. Grigoryev A., Savchuk S., Melnik A., Moskaleva N., Dzhurko J., Ershov M., et al. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:1126-1136.
48. Gronewold A., Skopp G. A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int 2011, 210:e7-e11.
49. Hájos N., Freund T.F. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 2002, 121:73-82.
50. Hill M.N., Sun J.C., Tse M.T., Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 2006, 9:277-286.
51. Hillebrand J., Olszewski D., Sedefov R. Legal highs on the Internet. Subst Use Misuse 2010, 45:330-340.
52. Ho B.Y., Zhao J. Determination of the cannabinoid receptors in mouse×rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett 1996, 212:123-126.
53. Hojo M., Sudo Y., Ando Y., Minami K., Takada M., Matsubara T., et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008, 108:308-319.
54. Hu X., Primack B.A., Barnett T.E., Cook R.L. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 2011, 6:16-19.
55. Hudson S., Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011, 3:466-478.
56. Hudson B.D., Hébert T.E., Kelly M.E. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010, 77:1-9.
57. Hudson S., Ramsey J., King L., Timbers S., Maynard S., Dargan P.I., et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in 'herbal high' products. J Anal Toxicol 2010, 34:252-260.
58. Huffman J.W. CB2 receptor ligands. Mini Rev Med Chem 2005, 5:641-649.
59. Huffman J.W. Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. The Cannabinoid Receptors 2009, 1:49-94. Humana Press, New York. P.H. Reggio (Ed.).
60. Huffman J.W., Padgett L.W. Recent developments in the medicinal chemistry of cannabinomimetic indoles, pyrroles and indenes. Curr Med Chem 2005, 12:1395-1411.
61. Huffman J.W., Dai D., Martin B.R., Compton D.R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 1994, 4:563-566.
62. Hurst D., Loeffler G., McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011, 168:1119.
63. Jack A. The story of Spice. The Financial Times Online, February 13 Available at, (accessed May 5, 2011). http://www.ft.com/cms/s/2/1721e2da-f8a0-11dd-aae8-000077b07658.html.
64. Jankovics P., Váradi A., Tölgyesi L., Lohner S., Németh-Palotás J., Balla J. Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary. Forensic Sci Int 2012, 214:27-32.
65. Järbe T.U., Deng H., Vadivel S.K., Makriyannis A. Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol 2011, 22:498-507.
66. Lapoint J., James L.P., Moran C.L., Nelson L.S., Hoffman R.S., Moran J.H. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011, 49:760-764.
67. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., et al. Spice: a never ending story?. Forensic Sci Int 2009, 2009(191):58-63.
68. Lombard C., Nagarkatti M., Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 2007, 122:259-270.
69. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006, 46:101-122.
70. Makriyannis, A., Deng, H., 2001. WO Patent 200128557. Cannabimimetic indole derivatives, granted 2001-06-07.
71. Marzouk L. Drug on open sale in Brighton. The Argus, February 20 Available at, (accessed February 20, 2009). http://www.theargus.co.uk/news/4143686.Super_drug_on_open_sale/.
72. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
73. McGrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M.R., et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010, 67:440-447.
74. Milligan G., Smith N.J. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 2007, 28:615-620.
75. Mir A., Obafemi A., Young A., Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128:1622-1627.
76. Möller I., Wintermeyer A., Bender K., Jübner M., Thomas A., Krug O., et al. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 2011, 3:609-620.
77. Moran J.H. Smart resource allocation needed to study 'legal highs'. Nat Med 2011, 17:1339.
78. Moran C.L., Le V.H., Chimalakonda K.C., Smedley A.L., Lackey F.D., Owen S.N., et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011, 83:4228-4236.
79. Müller H., Sperling W., Köhrmann M., Huttner H.B., Kornhuber J., Maler J.M. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010, 118:309-310.
80. Mustata C., Torrens M., Pardo R., Pérez C., Farré M. Spice drugs: cannabinoids as a new designer drugs. Adicciones 2009, 21:181-186.
81. Nakajima J., Takahashi M., Seto T., Suzuki J. Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the internet. Forensic Toxicol 2011, 29:51-55.
82. Nasser M.W., Qamri Z., Deol Y.S., Smith D., Shilo K., Zou X., et al. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 2011, 6:e23901.
83. Olea-Herrero N., Vara D., Malagarie-Cazenave S., Díaz-Laviada I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2. Br J Cancer 2009, 101:940-950.
84. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006, 1074:514-536.
85. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008, 3:e1640.
86. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008, 1139:434-449.
87. Penn H.J., Langman L.J., Unold D., Shields J., Nichols J.H. Detection of synthetic cannabinoids in herbal incense products. Clin Biochem 2011, 44:1163-1165.
88. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010, 62:588-631.
89. Phelps E.A., LeDoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 2005, 48:175-187.
90. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L., et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 2002, 948:155-158.
91. Psychonaut Web Mapping Research Group Psychonaut Web Mapping Project: Final Report 2010, Institute of Psychiatry, King's College London, London, UK.
92. Qamri Z., Preet A., Nasser M.W., Bass C.E., Leone G., Barsky S.H., et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009, 8:3117-3129.
93. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010, 215:598-605.
94. Schifano F., Deluca P., Baldacchino A., Peltoniemi T., Scherbaum N., Torrens M., et al. Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:640-646.
95. Schneir A.B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012, 8:62-64.
96. Schneir A.B., Cullen J., Ly B.T. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011, 40:296-299.
97. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?. Mol Interv 2011, 11:36-51.
98. Seely K.A., Brents L.K., Radominska-Pandya A., Endres G.W., Keyes G.S., Moran J.H., et al. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Curr Res Toxicol 2012, 4:825-827.
99. Simmons J., Cookman L., Kang C., Skinner C. Three cases of "spice" exposure. Clin Toxicol 2011, 49:431-433.
100. Simmons J.R., Skinner C.G., Williams J., Kang C.S., Schwartz M.D., Wills B.K. Intoxication from smoking "Spice". Ann Emerg Med 2011, 57:187-188.
101. Sobolevsky T., Prasolov I., Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010, 200:141-147.
102. Solinas M., Panlilio L.V., Justinova Z., Yasar S., Goldberg S.R. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 2006, 1:1194-1206.
103. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. Am J Psychiatry 2010, 167:1178-1193.
104. Teske J., Weller J.P., Fieguth A., Rothämel T., Schulz Y., Tröger H.D. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2659-2663.
105. Tomiyama K., Funada M. Cytotoxicity of synthetic cannabinoids found in "Spice" products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol Lett 2011, 207:12-17.
106. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010, 198:31-38.
107. Uchiyama N., Kawamura M., Kikura-Hanajiri R., Goda Y. Identification and quantitative analyses of two cannabimimetic phenylacetylindoles, JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles, JWH-081, JWH-015, JWH-200 and JWH-073, as designer drugs in illegal products. Forensic Toxicol 2011, 29:25-37.
108. 1 and CB[U+2082] receptors. Chem Pharm Bull 2011, 59:1203-1205.
109. UK Statutory Instrument No. 3209. Dangerous drugs. The Misuse of Drugs Act 1971 (Amendment) Order 2009 2009, Available at: http://www.opsi.gov.uk/si/si2009/pdf/uksi20093209 en.pdf (accessed August 13, 2010).
110. United Nation Office on Drugs and Crime (UNODC) World Drug Report 2011 2011, 175-193.
111. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012, 120:238-241.
112. Vann R.E., Warner J.A., Bushell K., Huffman J.W., Martin B.R., Wiley J.L. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol 2009, 615:102-107.
113. Vardakou I., Pistos C., Spiliopoulou C.H. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197:157-162.
114. Verster J.C. The popularity of "legal highs". Curr Drug Abuse Rev 2010, 3:196-199.
115. Wells D.L., Ott C.A. The "new" marijuana. Ann Pharmacother 2011, 45:414-417.
116. Westphal F., Sönnichsen F.D., Thiemt S. Identification of 1-butyl-3-(1-(4-methyl)naphthoyl)indole in a herbal mixture. Forensic Sci Int 2012, 215:8-13.
117. Wiley J.L., Barrett R.L., Lowe J., Balster R.L., Martin B.R. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 1995, 34:669-676.
118. Wiley J.L., Compton D.R., Dai D., Lainton J.A., Phillips M., Huffman J.W., et al. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 1998, 285:995-1004.
119. Wiley J.L., Marusich J.A., Martin B.R., Huffman J.W. 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend 2011, [Nov 27 Electronic publication ahead of print]. 10.1016/j.drugalcdep.2011.11.001.
120. Xi Z.X., Peng X.Q., Li X., Song R., Zhang H.Y., Liu Q.R., et al. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 2011, 14:1160-1166.
121. Young A.C., Schwarz E., Medina G., Obafemi A., Feng S.Y., Kane C., et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2011, [2011 Jul 28 Electronic publication ahead of print]. 10.1016/j.ajem.2011.05.013.
122. Yücel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008, 65:694-701.
123. Zawilska J.B. "Legal Highs" - new players in the old drama. Curr Drug Abuse Rev 2011, 4:122-130.
124. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "Spice Gold". Dtsch Artzebl Int 2009, 106:464-467.
125. Zuba D., Byrska B., Maciow M. Comparison of "herbal highs" composition. Anal Bioanal Chem 2011, 400:119-126.